MedTrace Logo

SAHaRA: A Randomized Controlled Trial

NCT03309579 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 742

Last updated 2024-11-06

No results posted yet for this study

Summary

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal

Interventions

OTHER

Liberal RBC Transfusion Strategy

RBC transfusion is triggered by a Hemoglobin value of ≤100g/L

OTHER

Restrictive RBC Transfusion Strategy

Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Shane English, MD MSc FRCPC · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-12
Primary Completion
2024-07-10
Completion
2024-08-22

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309579 on ClinicalTrials.gov